Toll样受体与急性白血病合并感染  

Toll-like Receptor and Acute Leukemia Complicated with Infection——Review

作　　者：李雪卿[1] 苏丽萍[1] 

机构地区：[1]山西医科大学第二临床医学院血液内科,太原030001

出　　处：《中国实验血液学杂志》2007年第3期667-670,共4页Journal of Experimental Hematology

摘　　要：感染与抗生素多重耐药已成为急性白血病临床所关注的焦点问题,使抗感染治疗面临新的挑战。To11样受体(Toll-like receptor,TLR)是新近发现的天然免疫受体,在免疫应答中的重要性受到广泛关注,对TLR研究的进一步深入,必将使感染、抗感染免疫的理论研究取得新的突破,并对急性白血病合并感染等的临床治疗起指导性作用。本文对TLR及其在急性白血病合并感染中表达的意义和研究现状作一综述。Infection and antibiotic multidrug resistance have become the focal issue in clinical treatment of acute leukemia and will make anti-infection therapy facing to new challenge. Toll-like receptor （TLR） has been found a newly innate immunoreceptor. It is significant in immune response, Along with further investigation of TLR, infection and anti-infection immunity theory would gain a new breakthrough and play a guiding role in clinical treatment of acute leukemia complicated with infection, In this review, the progress in the research of TLR and its expression in acute leukemia complicated with infection were summarized.

关 键 词：TOLL样受体 急性白血病 感染 抗生素 多重耐药 

分 类 号：R733.71[医药卫生—肿瘤]